DS
BIOS

David Shaw’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

David Shaw’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-893,470
Closed -$9.33M – 4720
2023
Q1 		$9.33M Buy
893,470
+88,690
+11% +$919K 0.01% 1429
2022
Q4 		$8.27M Buy
804,780
+100
+0% +$1.01K 0.01% 1610
2022
Q3 		$8.09M Buy
804,680
+200
+0% +$2K 0.01% 1546
2022
Q2 		$8.09M Buy
804,480
+38,980
+5% +$387K 0.01% 1591
2022
Q1 		$7.56M Buy
+765,500
New +$7.55M 0.01% 1876

Other funds holding BIOS

WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
QL
Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

David Shaw's BIOS Position: Q2 2023 in Review

David Shaw sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 893,470 shares — an estimated $9.33M sold.

David Shaw first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $9.33M in Q1 2023. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

  • David Shaw reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • David Shaw sold 893,470 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $9.33M.
  • David Shaw first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
  • David Shaw's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $9.33M in Q1 2023.
  • 32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.